Enhanced Analytical Performance in CYFRA 21-1 Detection Using Lateral Flow Assay with Magnetic Bioconjugates:...

Area of Science:

• Biomarker Detection
• Assay Development
• Point-of-Care Diagnostics

Background:

• CYFRA 21-1 is a key biomarker for epithelial-origin cancers.
• Developing sensitive and rapid detection methods is crucial for early cancer diagnosis.
• Lateral flow assays (LFAs) offer convenience but often lack the sensitivity of laboratory-based tests.

Purpose of the Study:

• To develop a novel, highly sensitive LFA for CYFRA 21-1 detection.
• To compare magnetic particle quantification (MPQ) with traditional optical detection in LFAs.
• To validate the assay's performance in clinically relevant samples.

Main Methods:

• Utilized magnetic bioconjugates (MBCs) with LFAs.
• Integrated label-free spectral-phase interferometry, colorimetric detection, and MPQ.
• Compared MPQ-based and colorimetry-based detection methods side-by-side.

Main Results:

• MPQ achieved a limit of detection (LOD) of 0.9 pg/mL, outperforming optical detection (2.9 pg/mL).
• MPQ demonstrated elimination of signal saturation, higher sensitivity, and a 19-fold wider dynamic range.
• Assay results were comparable to laboratory tests, with a 20-minute assay duration.

Conclusions:

• MPQ-based detection significantly enhances LFA performance for CYFRA 21-1.
• The developed LFA offers rapid, reliable, and sensitive biomarker detection.
• This approach holds great potential for point-of-care diagnostics, especially in resource-limited settings.